|
|
||||||||||||||
|
|
|||||||||||||||
PAPER |
1 Department of Neurosciences, University of Padova, Italy
2 Childrens Hospital of Pittsburgh, Division of Pediatric Endocrinology, Pittsburgh, PA, USA
3 Center for Genetic Medicine, Childrens Research Hospital, Washington, DC, USA
Correspondence to:
Correspondence to:
Dr E Pegoraro
Department of Neurosciences, University of Padova, via Giustiniani 5, 35128 Padova, Italy; elena.pegoraro{at}unipd.it
Background: Steroid administration is beneficial in Duchenne muscular dystrophy (DMD), but the response, incidence, and the severity of side effects are variable.
Aims: To investigate whether glucocorticoid receptor (GRL) gene polymorphisms may be responsible for glucocorticoid sensitivity in DMD.
Methods: Forty eight DMD patients treated either with prednisone or deflazacort were subjected to genetic analyses of the GRL gene.
Results: Mutation studies revealed an heterozygous A to G mutation at GRL cDNA position 1220 in three DMD patients resulting in an asparagine to serine amino acid change at amino acid position 363 (N363S). The N363S carrier DMD patients showed a trend towards a later age at loss of ambulation in comparison with non-carrier patients.
Conclusions: These data suggest that the N363S GRL polymorphism may be implicated in the long term response to glucocorticoids.
Abbreviations: DMD, Duchenne muscular dystrophy; PCR, polymerase chain reaction; SSCP, single strand conformational polymorphism
Keywords: Duchenne muscular dystrophy; glucocorticoid receptor; SNP; steroid therapy
Related Article
J. Neurol. Neurosurg. Psychiatry 2006 77: 1104-1105.
This article has been cited by other articles:
![]() |
N Nirmalananthan and M G Hanna Predicting steroid response in muscle disease J. Neurol. Neurosurg. Psychiatry, October 1, 2006; 77(10): 1104 - 1105. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |